The hormone that controls the immune system may open new cancer treatments

“Skilled cells are among the first group of immune cells appointed in the tumors, but very quickly these combat cells of the tumor turn into cells that support the tumor. Our study indicates that these pelvic cell receptors are stimulated by these hormones and ends up to the suppression of the immune system.” Southwest. Dr. Zhang participated in the study with the first author Shing Yang, PhD, post -PhD researcher at the Chang Laboratory.

Dr. Chang said current immune treatments, such as immune checkpoint inhibitors, said only for about 20 % to 30 % of cancer patients, indicating that there are multiple methods that cancer evades from the immune system.

Several years ago, researchers at the Zhang Laboratory who study immunity cells to combat cancer called a reinforcement cells in the future has identified inhibitors called Lilrb4. This future stimulated the ability of marrow cells to attack tumors.

Dr. Chang, Dr. Yang and their colleagues then a genome screen for all proteins that may interact with Lilrb4. It was a promising hormone blow called SCG2. Although researchers suggested that SCG2 plays a role in the immune response, its function and receptors were not known. Laboratory experiments confirmed that SCG2 is associated with Lilrb4, which leads to the start of a series of signals that extinguish the capabilities of cancer in the marrow cells and prevent their ability to recruit T cells to combat cancer in tumors.

In the genetically changed mice to express the human form of Lilrb4, the injected cancer cells that produced Scg2 rapidly have grown. Treating these mice with an antibiotic body that blocks Lilrb4 is a great growth in the growth of cancer, as it did artificially on the bodies of animal from SCG2.

These experiments indicate that the reactions between Lilrb4 and SCG2 allow cancer to grow without deterrent from the marrow cells, T cells, and other immune cells. Dr. Zhang suggested that disable this reaction can one day provide a new option for immunotherapy to treat cancer. On the contrary, since this reaction deviates the immunity activity of the spinal cells, an additional SCG2 provision can be a promising treatment for immune or inflammatory disorders paid by the spinal cells. Dr. Zhang and his colleagues are planning to investigate both ideas in future studies.

Among the other researchers in UTSW who contributed to this study Xuewu Zhang, doctorate, professor of pharmacology and biotechnology; Sherrill Lewis, PhD, Associate Professor at the Simples Center for Cancer and Pathology; Lynn Show, PhD, Assistant Professor at Peter Odonil Junior for Public Health and Pediatrics; Jingjing XIE, PhD, Physiology Coach; Qi Lou, PhD, Assistant Teacher in Physiology; Lei Guo, Doctorate, Massion Biology; And Ming Fang, Ph.d. , Chengcheng Zhang, Ph.d. , Ankit gupta, ph.d. , And Lianqi Chen, Ph.d. , Postdoctoral Proversion.

Dr. Alack Zhang holds Professor Horting L. Morton e. Sanger in oncology and a researcher in Michael L. Rosenberg in medical research. Dr. Xuewu Zhang and Dr. Show are members of the Simmons Cancer Center.

This study was funded by grants provided by the National Cancer Institute (NCI) (R01CA248736, R01CA263079, and Al Bhazat Development Research Program 779), Cancer Prevention and Research Institute in Texas (RP220032, RP15150551, RP190561). I-1702), IMMUNE-Onec Therapics Inc. (Research Scholarship No. 111077), National Institutes of Health (R35GM130289), and NCI Cancer Support grant (P30CA142543).

The University of Texas has a financial interest in immunity in the form of property and licensing rights. Dr. Alack Zhang holds property rights to sponsor research agreements with immunity.